Bhattacharyya GS et al., conducted a Phase I/II trial that included 400 patients divided into two groups, diagnosed with hormone receptor-positive and HER2-negative breast cancer, who received tamoxifen and sirolimus 2 mg daily. Here, ERBB2 is linked to breast carcinoma.